[{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AGN-151587","moa":"CEP290","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Azzur Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Editas Medicine"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Termination","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Gamma-delta T Cell Adoptive Cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"2","companyTruncated":"Editas Medicine \/ Immatics"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"AAV5 vectors gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Shoreline Biosciences"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Azzur Group","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Editas Medicine"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Editas Medicine \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Alpha-beta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":3.8900000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":3.8900000000000001,"dosageForm":"","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Renizgamglogene Autogedtemcel","moa":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Editas Medicine \/ DRI Healthcare Trust","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"mRNA-CRISPR- based Therapy","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Editas Medicine \/ Editas Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Editas Medicine"}]
Find Clinical Drug Pipeline Developments & Deals by Editas Medicine
Details :
The collaboration aims to combine Editas’s CRISPR Cas12a genome editing systems with Genevant’s LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets.
Details :
The proceeds will be used to enable further pipeline development, including EDIT-301 (renizgamglogene autogedtemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.
Details :
The collaboration aims to focus on the research, develop, and commercialize of autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
Details :
Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including Casgevy (exagamglogene autot...
Details :
EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, which demonstrated a sustained increase in fetal hemoglobin production in patients with with severe SCD and TDT.
Details :
The partnersip aims to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to co...
Details :
EDIT-301 consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, which demonstrated a sustained increase in fetal
hemoglobin production in patients with with severe SCD and TDT...
Details :
Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufa...
Details :
EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Details :
EDIT-101 is a CRISPR/Cas9-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10), by deleting the IVS26 CEP290 mutant allele.
Reset All
